Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary)
- Indications Mesothelioma; Pleural disorders
- Focus Therapeutic Use
- Acronyms PrE0505
- 01 May 2017 Status changed from not yet recruiting to recruiting.
- 03 Mar 2017 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 03 Mar 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020.